Spero Therapeutics to Present at Investor Conferences in November
Spero Therapeutics (SPRO) will participate in the Guggenheim healthcare conference on November 10 and the Jefferies healthcare conference on November 18–19, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spero Therapeutics (SPRO) will participate in the Guggenheim healthcare conference on November 10 and the Jefferies healthcare conference on November 18–19, 2026. CEO Esther Rajavelu will join a fireside chat at 10:30 AM ET at Guggenheim in Boston. Management will also be available for investor meetings at both conferences, with the Jefferies event taking place in London.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that Esther Rajavelu, President and Chief Executive Officer, will participate in a “fireside chat” at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA. The company's leadership team will be available for one-on-one meetings with investors. The team will also participate in the Jefferies Global Healthcare Conference in London, UK where they will be available for meetings with investors.
| Guggenheim 3rd Annual Healthcare Innovation Conference | |
| Date: | Tuesday, November 10 |
| Time: | 10:30 AM ET |
| Location: | Boston, MA |
| Webcast Link: | click here |
| Jefferies Global Healthcare Conference | |
| Dates: | November 18-19 |
| Location: | London, UK |
To request a meeting with management please reach out to your institutional contact at the respective conference.
About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotx.com
Media Inquiries:
media@sperotx.com
